| 000 | 01789 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515130330.0 | ||
| 264 | 0 | _c20081218 | |
| 008 | 200812s 0 0 eng d | ||
| 022 | _a1074-2484 | ||
| 024 | 7 |
_a10.1177/1074248408321461 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFerrer-García, Juan Carlos | |
| 245 | 0 | 0 |
_aEfficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. _h[electronic resource] |
| 260 |
_bJournal of cardiovascular pharmacology and therapeutics _cSep 2008 |
||
| 300 |
_a183-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 |
_aCholesterol, HDL _xblood |
| 650 | 0 | 4 |
_aCholesterol, LDL _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeptanoic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHyperlipidemias _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrroles _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriglycerides _xblood |
| 700 | 1 | _aSanchez-Ballester, Eva | |
| 700 | 1 | _aAlbalat-Galera, Raquel | |
| 700 | 1 | _aBerzosa-Sanchez, Miguel | |
| 700 | 1 | _aHerrera-Ballester, Agustín | |
| 773 | 0 |
_tJournal of cardiovascular pharmacology and therapeutics _gvol. 13 _gno. 3 _gp. 183-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1074248408321461 _zAvailable from publisher's website |
| 999 |
_c18116142 _d18116142 |
||